C. Turkington

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.

D. Cunningham, B. Karaszewska, M. Tejani, 2017, The Lancet. Oncology.